📣 VC round data is live. Check it out!

Integra Lifesciences Valuation Multiples

Discover Integra Lifesciences' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Shinva, Butterfly Network, Enovis, Avanos Medical and more.

Integra Lifesciences Overview

About Integra Lifesciences

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.


Founded

1969

HQ

United States

Employees

4.4K

Financials (LTM)

Revenue: $2B
EBITDA: $323M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Integra Lifesciences Financials

Integra Lifesciences reported last 12-month revenue of $2B and EBITDA of $323M.

In the same LTM period, Integra Lifesciences generated $1B in gross profit, $323M in EBITDA, and $179M in net income.

Revenue (LTM)


Integra Lifesciences P&L

In the most recent fiscal year, Integra Lifesciences reported revenue of $2B and EBITDA of $316M.

Integra Lifesciences is profitable as of last fiscal year, with gross margin of 51%, EBITDA margin of 19%, and net margin of 10%.

See analyst estimates for Integra Lifesciences
LTMLast FY202320242025202620272028
Revenue$2B$2B$2B$2B$2B
Gross Profit$1B$832M$885M$882M$832M
Gross Margin62%51%57%55%51%
EBITDA$323M$316M$256M$193M($325M)
EBITDA Margin20%19%17%12%(20%)
EBIT Margin17%17%7%2%1%
Net Profit$179M$171M$68M($7M)($516M)
Net Margin11%10%4%(0%)(32%)
Net Debt-$2B---

Financial data powered by Morningstar, Inc.

Integra Lifesciences Stock Performance

Integra Lifesciences has current market cap of $1B, and enterprise value of $3B.

Market Cap Evolution


Integra Lifesciences' stock price is $15.65.

Integra Lifesciences share price decreased by 2.4% in the last 30 days, and increased by 27.5% in the last year.

Integra Lifesciences has an EPS (earnings per share) of $2.20.

See more trading valuation data for Integra Lifesciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$1B-0.2%-2.4%66.1%27.5%$2.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Integra Lifesciences Valuation Multiples

Integra Lifesciences trades at 1.8x EV/Revenue multiple, and 9.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Integra Lifesciences

EV / Revenue (LTM)


Integra Lifesciences Financial Valuation Multiples

As of June 3, 2026, Integra Lifesciences has market cap of $1B and EV of $3B.

Integra Lifesciences has a P/E ratio of 6.8x.

LTMLast FY202320242025202620272028
EV/Revenue1.8x1.8x1.9x1.9x1.8x
EV/EBITDA9.3x9.5x11.7x15.5x(9.2x)
EV/EBIT10.7x11.0x26.8x105.3x166.2x
EV/Gross Profit2.9x3.6x3.4x3.4x3.6x
P/E6.8x7.1x18.0x(175.3x)(2.4x)
EV/FCF43.9x(96.3x)40.9x199.3x(66.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Integra Lifesciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Integra Lifesciences Margins & Growth Rates

Integra Lifesciences grew revenue by 2% and EBITDA by 6% in the last fiscal year.

In the most recent fiscal year, Integra Lifesciences reported gross margin of 51%, EBITDA margin of 19%, and net margin of 10%.

See estimated margins and future growth rates for Integra Lifesciences

Integra Lifesciences Margins

Last FY202420252026202720282029
Gross Margin51%55%51%62%
EBITDA Margin19%12%(20%)20%
EBIT Margin17%2%1%17%
Net Margin10%(0%)(32%)11%
FCF Margin(2%)1%(3%)12%

Integra Lifesciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth2%4%2%2%
Gross Profit Growth26%(0%)(6%)26%
EBITDA Growth6%(24%)(268%)(202%)
EBIT Growth7%(75%)(37%)1512%
Net Profit Growth10%(110%)7338%(137%)
FCF Growth(758%)(79%)(401%)(551%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Integra Lifesciences Operational KPIs

Integra Lifesciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Integra Lifesciences' Rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Integra Lifesciences' Rule of X is 26% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Integra Lifesciences
LTMLast FY202320242025202620272028
Rule of 4022%22%---
Bessemer Rule of X27%26%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
R&D Expenses to Revenue5%6%7%7%6%
Opex to Revenue-50%50%53%50%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Integra Lifesciences Competitors

Integra Lifesciences competitors include Shinva, Butterfly Network, Enovis, Avanos Medical, Inspire Medical Systems, Tandem Diabetes Care, SonoScape, Sinocare, Alphatec Holdings and iRadimed.

Most Integra Lifesciences public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Shinva0.6x0.6x7.1x7.1x
Butterfly Network11.1x10.1x(40.7x)(43.1x)
Enovis1.2x1.2x6.6x6.4x
Avanos Medical1.8x1.8x14.3x14.0x
Inspire Medical Systems1.0x1.0x4.5x4.8x
Tandem Diabetes Care1.4x1.4x(31.2x)(430.9x)
SonoScape3.3x3.1x27.8x24.6x
Sinocare1.9x1.8x22.4x17.2x

This data is available for Pro users. Sign up to see all Integra Lifesciences competitors and their valuation data.

Start Free Trial

Acquisitions by Integra Lifesciences

Integra Lifesciences has acquired 12 companies to date.

Last acquisition by Integra Lifesciences was on December 13th 2023. Integra Lifesciences acquired Acclarent for $280M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Integra Lifesciences

Acclarent
Surgical Innovation Associates
ACell
Rebound Therapeutics
Description
Acclarent is an Irvine-based medical device company specializing in minimally invasive sinus treatments. Acquired by Johnson & Johnson in 2012, it offers Balloon Sinuplasty devices cleared by FDA in 2005 for dilating sinus passages without tissue removal. The Relieva product line supports over one million procedures performed globally.
-
ACell is a regenerative medicine company commercializing MatriStem extracellular matrix devices for wound, plastic surgery, and hernia repair. Columbia, Maryland-headquartered since 1999, it manufactures acellular porcine matrices at its Lafayette, Indiana plant. ACell's products promote tissue remodeling in urology and general surgery, with FDA clearances for over 20 indications and distribution in 40 countries.
Rebound Therapeutics is an Austin-based medical device company developing tools for minimally invasive surgery. Its product line features articulating access sheaths and tissue retractors improving visualization in neuro and spinal procedures. Holding 14 US patents, Rebound conducted preclinical studies in animal models leading to first-in-human trials in 2019. The firm assembled advisors from Mayo Clinic and Johns Hopkins.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Chicago, IL
Baltimore, MD
Los Angeles, CA
Deal Date13 Dec 20231 Dec 202216 Dec 20209 Sep 2019
Valuation$280M$140M$400M$102M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Integra Lifesciences acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Integra Lifesciences

Integra Lifesciences has invested in 1 company to date.

Latest investment by Integra Lifesciences was on September 17th 2014. Integra Lifesciences invested in Avraham Pharmaceuticals in their $5M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Integra Lifesciences

Avraham Pharmaceuticals
Description
Avraham Pharmaceuticals is a Israel-based biopharmaceutical company advancing ladostigil for Alzheimer's disease and other neurodegenerative conditions. Founded in 2010 in Ness Ziona, the firm completed a Phase II trial in Europe supported by $9 million in funding and continues preclinical work on Parkinson's therapies.
HQ CountryIsrael
HQ City
Yavne
Deal Date17 Sep 2014
RoundSeed
Raised$5M
InvestorsIntegra Lifesciences
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Integra Lifesciences investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Integra Lifesciences

When was Integra Lifesciences founded?Integra Lifesciences was founded in 1969.
Where is Integra Lifesciences headquartered?Integra Lifesciences is headquartered in United States.
How many employees does Integra Lifesciences have?As of today, Integra Lifesciences has over 4K employees.
Who is the CEO of Integra Lifesciences?Integra Lifesciences' CEO is Mojdeh Poul.
Is Integra Lifesciences publicly listed?Yes, Integra Lifesciences is a public company listed on Nasdaq.
What is the stock symbol of Integra Lifesciences?Integra Lifesciences trades under IART ticker.
When did Integra Lifesciences go public?Integra Lifesciences went public in 1995.
Who are competitors of Integra Lifesciences?Integra Lifesciences main competitors include Shinva, Butterfly Network, Enovis, Avanos Medical, Inspire Medical Systems, Tandem Diabetes Care, SonoScape, Sinocare, Alphatec Holdings, iRadimed.
What is the current market cap of Integra Lifesciences?Integra Lifesciences' current market cap is $1B.
What is the current revenue of Integra Lifesciences?Integra Lifesciences' last 12 months revenue is $2B.
What is the current revenue growth of Integra Lifesciences?Integra Lifesciences revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of Integra Lifesciences?Current revenue multiple of Integra Lifesciences is 1.8x.
What is the current EBITDA of Integra Lifesciences?Integra Lifesciences' last 12 months EBITDA is $323M.
What is Integra Lifesciences' EBITDA margin?Integra Lifesciences' last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Integra Lifesciences?Current EBITDA multiple of Integra Lifesciences is 9.3x.
What is the current FCF of Integra Lifesciences?Integra Lifesciences' last 12 months FCF is $68M.
What is Integra Lifesciences' FCF margin?Integra Lifesciences' last 12 months FCF margin is 4%.
What is the current EV/FCF multiple of Integra Lifesciences?Current FCF multiple of Integra Lifesciences is 43.9x.
How many companies Integra Lifesciences has acquired to date?As of June 2026, Integra Lifesciences has acquired 12 companies.
What was the largest acquisition by Integra Lifesciences?$1B acquisition of Codman Neuro on 2nd October 2017 was the largest M&A Integra Lifesciences has done to date.
What companies Integra Lifesciences acquired?Integra Lifesciences acquired Codman Neuro, ACell, TEI Biosciences Inc, Acclarent, Confluent Surgical, Derma Sciences, Surgical Innovation Associates, Rebound Therapeutics, Medtronic Xomed Instrumentation SAS, Arkis BioSciences, and 2 other companies.
In how many companies Integra Lifesciences has invested to date?As of June 2026, Integra Lifesciences has invested in 1 company.
What was the last Integra Lifesciences investment?On 17th September 2014 Integra Lifesciences invested in Avraham Pharmaceuticals, participating in a $5M Seed round.
In what companies Integra Lifesciences invested in?Integra Lifesciences invested in Avraham Pharmaceuticals.

See public comps similar to Integra Lifesciences

Lists including Integra Lifesciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial